[Featured Stock] Nextbiomedical Rises on US FDA Clinical Trial Plan Approval... New High

Nextbiomedical is showing strong gains in early trading following the news of the U.S. Food and Drug Administration (FDA) approval of the clinical trial plan (IDE) for its musculoskeletal pain embolization treatment 'Nexphere F'. The stock hit a 52-week high during the session.

As of 9:11 a.m. on the 2nd, Nextbiomedical was trading at 36,400 KRW, up 700 KRW (1.96%) from the previous close. During the session, it rose to 39,200 KRW, setting a new 52-week high.

On the same day, Nextbiomedical announced that it had received FDA approval for the clinical trial plan of Nexphere F. The approved U.S. pivotal clinical trial will be a multicenter, randomized, open-label study conducted at 20 major university hospitals across the United States, involving 120 patients to evaluate the efficacy and safety of Nexphere F.